Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
Type:
Application
Filed:
October 25, 2013
Publication date:
August 14, 2014
Applicants:
Ludwig Institute for Cancer, Institut Pasteur
Inventors:
Gilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
Abstract: The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of STM/Hop to PrPc. The invention is directed to methods for treating cancer which rely on interfering with the Hop-PrPc interaction and to peptides, and antibodies raised against the peptides, which directly provide that interference. The invention is further based on the discovery that STI1230-245 peptide and its human homologue Hop23o-245 provide the desired interference with the STI1/Hop-PrPc interaction and inhibit the STI 1/Hop-induced proliferation of glioma and glioblastoma cells. The invention is thus further directed to methods of treating cancer that employ these peptides and functional derivatives thereof, and antibodies directed to the peptides and derivatives. The invention is further directed to means of treating cancer which involve reducing the effective amount of Hop or reducing the expression of Hop.
Type:
Grant
Filed:
September 17, 2008
Date of Patent:
August 12, 2014
Assignee:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Rafael Bierig Erlich, Luciana Chiarini, Vilma R. Martins, Rafael Linden, Vivaldo Moura Neto
Abstract: Among the methods, compositions, combinations and kits provided herein are those for determining gene expression levels in one or more cell types in heterogeneous cell samples, for identifying genes differentially expressed in different cell types, and for detecting a cell type in a sample from a subject. Also provided herein are methods, compositions, combinations and kits for determining gene expression levels in cells corresponding to phenotypes, and for identifying a phenotype of a subject by detecting differentially expressed genes.
Type:
Grant
Filed:
January 10, 2005
Date of Patent:
July 15, 2014
Assignees:
The Regents of the University of California, Sidney Kimmel Cancer Center, Ludwig Institute for Cancer Research
Inventors:
William Wachsman, Daniel Mercola, Michael McClelland, Jessica Wang-Rodriguez, David Tarin, Charles C. Berry, Karen Arden, Linda Wasserman, Steven Goodison, Igor Klacansky, Elizabeth Duff Stuart
Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.
Type:
Grant
Filed:
February 28, 2012
Date of Patent:
July 1, 2014
Assignees:
Ludwig Institute for Cancer Research, University of Maryland, The Regents of the University of Michigan
Inventors:
Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
Abstract: Disclosed herein are methods to inhibit cleavage of a type I receptor of transforming growth factor beta (T?RI) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of T?RI and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of T?RI, which is a product of T?RI cleavage.
Type:
Application
Filed:
March 13, 2012
Publication date:
May 22, 2014
Applicant:
Ludwig Institute for Cancer Research Ltd.
Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
Type:
Application
Filed:
September 24, 2013
Publication date:
May 1, 2014
Applicants:
UCL Business PLC, Ludwig Institute for Cancer Research
Inventors:
Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
March 25, 2014
Assignee:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Klaus-Dieter Preuss, Michael Pfreundschuh
Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
Type:
Application
Filed:
December 22, 2011
Publication date:
February 20, 2014
Applicant:
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
Type:
Grant
Filed:
January 29, 2010
Date of Patent:
February 18, 2014
Assignees:
Ludwig Institute for Cancer Research Ltd., Massachusetts Institute for Technology, Commonwealth Scientific and Industrial Research Organization
Inventors:
Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
Abstract: The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.
Type:
Grant
Filed:
January 29, 2009
Date of Patent:
December 10, 2013
Assignees:
Ludwig Institute for Cancer Research, Ltd., Institute of Molecular Biology and Genetics National Academy of Science of Ukraine, Sloan-Kettering Institute for Cancer Research
Inventors:
Gerd Ritter, Beatrice Yin, Anne Murray, George Mark, Lloyd Old, Kenneth Lloyd, Serhiy Souchelnytskiy, Ivan Gout, Valeriy Filonenko, Ramziya Kiyamova
Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
Type:
Application
Filed:
July 30, 2013
Publication date:
November 14, 2013
Applicants:
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD., CSL LIMITED
Inventors:
Brendan J. JENKINS, Tracy Lynn PUTOCZKI, Matthias ERNST, Andrew JARNICKI, Brent MCKENZIE
Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
Type:
Application
Filed:
September 30, 2011
Publication date:
October 31, 2013
Applicant:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
September 24, 2013
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
Abstract: Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.
Type:
Application
Filed:
September 1, 2011
Publication date:
August 29, 2013
Applicant:
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Inventors:
Bruno Galvao Filho, Ricardo Tostes Gazzinelli, Caroline Junqueira Giusta, Santuza Maria Ribeiro Teixeira
Abstract: The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same.
Type:
Grant
Filed:
October 14, 2009
Date of Patent:
August 27, 2013
Assignees:
CSL Limited, Ludwig Institute for Cancer Research Ltd.
Inventors:
Brendan J. Jenkins, Tracy Lynn Putoczki, Matthias Ernst, Andrew Jarnicki, Brent McKenzie
Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
Type:
Grant
Filed:
February 3, 2009
Date of Patent:
August 27, 2013
Assignee:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Lan-Qing Huang, Aline van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
Abstract: The invention relates to CTSP polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, CTSP-1.
Type:
Grant
Filed:
May 2, 2012
Date of Patent:
June 25, 2013
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Raphael Bessa Parmigiani, Maria Dulcetti Vibranovski, Sandro José de Souza, Anamaria Aranha Camargo
Abstract: The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.
Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
Type:
Grant
Filed:
September 15, 2011
Date of Patent:
May 14, 2013
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Gerd Ritter, Lloyd Old, Achim Jungbluth, Cynthia H. Scanlan